BridgeBio Pharma Management

Management criteria checks 2/4

BridgeBio Pharma's CEO is Neil Kumar, appointed in Apr 2015, has a tenure of 9.25 years. total yearly compensation is $12.16M, comprised of 6.1% salary and 93.9% bonuses, including company stock and options. directly owns 3.69% of the company’s shares, worth €164.11M. The average tenure of the management team and the board of directors is 5.5 years and 4.5 years respectively.

Key information

Neil Kumar

Chief executive officer

US$12.2m

Total compensation

CEO salary percentage	6.1%
CEO tenure	9.3yrs
CEO ownership	3.7%
Management average tenure	5.5yrs
Board average tenure	4.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Neil Kumar's remuneration changed compared to BridgeBio Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$538m
Dec 31 2023	US$12m	US$742k	-US$643m
Sep 30 2023	n/a	n/a	-US$613m
Jun 30 2023	n/a	n/a	-US$573m
Mar 31 2023	n/a	n/a	-US$425m
Dec 31 2022	US$7m	US$1m	-US$481m
Sep 30 2022	n/a	n/a	-US$491m
Jun 30 2022	n/a	n/a	-US$509m
Mar 31 2022	n/a	n/a	-US$596m
Dec 31 2021	US$26m	US$725k	-US$563m
Sep 30 2021	n/a	n/a	-US$535m
Jun 30 2021	n/a	n/a	-US$495m
Mar 31 2021	n/a	n/a	-US$520m
Dec 31 2020	US$10m	US$550k	-US$449m
Sep 30 2020	n/a	n/a	-US$402m
Jun 30 2020	n/a	n/a	-US$346m
Mar 31 2020	n/a	n/a	-US$291m
Dec 31 2019	US$26m	US$503k	-US$261m
Sep 30 2019	n/a	n/a	-US$226m
Jun 30 2019	n/a	n/a	-US$197m
Mar 31 2019	n/a	n/a	-US$155m
Dec 31 2018	US$450k	US$450k	-US$131m

Compensation vs Market: Neil's total compensation ($USD12.16M) is above average for companies of similar size in the German market ($USD3.60M).

Compensation vs Earnings: Neil's compensation has increased whilst the company is unprofitable.

CEO

Neil Kumar (45 yo)

9.3yrs

Tenure

US$12,158,626

Compensation

Dr. Neil Kumar, Ph D., has been Director of Lianbio since October 2019. He is a Co-Founder of BridgeBio Pharma, Inc. and serves as its Chief Executive Officer and Director since April 2015.He serves as Pr...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Neil Kumar	Co-Founder	9.3yrs	US$12.16m	3.69% $ 164.1m
Charles Homcy	Co-Founder	no data	US$1.11m	0.66% $ 29.2m
Frank McCormick	Co-Founder	no data	US$1.74m	0.59% $ 26.1m
Brian Stephenson	CFO & Secretary	5.8yrs	US$6.65m	0.041% $ 1.8m
Richard Scheller	Chairman of Research & Development	5.5yrs	US$2.01m	no data
Uma Sinha	Chief Scientific Officer	8.3yrs	US$2.75m	no data
Grace Rauh	Vice President of Communications	no data	no data	no data
Eli Wallace	Chief Scientific Officer of Oncology	4.6yrs	no data	no data
Thomas Trimarchi	Chief Product Officer	no data	no data	no data
Eric David	Chief Executive Officer of Gene Therapy	no data	no data	no data
Matthew Outten	Chief Commercial Officer	3.2yrs	no data	no data
Adora Ndu	Chief Regulatory Affairs Officer	2.5yrs	no data	no data

5.5yrs

Average Tenure

54.5yo

Average Age

Experienced Management: 2CL's management team is seasoned and experienced (5.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Neil Kumar	Co-Founder	9.3yrs	US$12.16m	3.69% $ 164.1m
Charles Homcy	Co-Founder	5.7yrs	US$1.11m	0.66% $ 29.2m
Frank McCormick	Co-Founder	less than a year	US$1.74m	0.59% $ 26.1m
Fred Hassan	Independent Director	2.9yrs	US$600.00k	0.010% $ 458.5k
Ronald Daniels	Independent Director	4.4yrs	US$600.00k	0.0056% $ 247.2k
Eric Aguiar	Independent Director	5.3yrs	US$600.00k	0% $ 0
Randal Scott	Independent Director	4.1yrs	US$600.00k	0.0048% $ 213.9k
Ali Satvat	Independent Director	8.3yrs	US$600.00k	0% $ 0
James Momtazee	Director	8.3yrs	US$600.00k	0.047% $ 2.1m
Jennifer Cook	Director	4.6yrs	US$600.00k	0.0038% $ 169.9k
Wen-Chaun Lo	Independent Director	4.1yrs	US$600.00k	0.14% $ 6.0m
Andrea Ellis	Independent Director	2.9yrs	US$600.00k	0.0064% $ 285.0k

4.5yrs

Average Tenure

62.5yo

Average Age

Experienced Board: 2CL's board of directors are considered experienced (4.5 years average tenure).

BridgeBio Pharma Management

Management criteria checks 2/4

Key information

Recent management updates

BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024

BridgeBio Pharma, Inc., Annual General Meeting, Jun 22, 2022

Independent Director recently bought €264k worth of stock

Recent updates

BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Pharma, Inc. Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024

BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

BridgeBio Pharma, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$3.95 loss per share (vs US$3.26 loss in FY 2022)

New major risk - Financial position

BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

BridgeBio Pharma, Inc. Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy in the New England Journal of Medicine

BridgeBio Pharma, Inc. Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

BridgeBio Pharma, Inc. Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

BridgeBio Pharma, Inc. Shares Positive Long-Term Data from an Ongoing Phase 2 Study, Which Support the Potential Use of Glycosylated Alpha-dystroglycan (DG) Levels as a Surrogate Endpoint in Limb-Girdle Muscular Dystrophy Type 2I/R9

BridgeBio Pharma, Inc. announced that it expects to receive $250.003806 million in funding from Qatar Investment Authority and other investors

BridgeBio Pharma, Inc. announced that it expects to receive $250.003806 million in funding from Qatar Investment Authority and other investors

Bridgebio Pharma Announces Positive Feedback from the U.S. Fda and Eu Ema on the Regulatory Path for A Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

BridgeBio Pharma, Inc. Presents Detailed Positive Results from Phase 3 Attribute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) At European Society of Cardiology Congress 2023

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$0.067 loss in 2Q 2022)

Bridgebio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-Girdle Muscular Dystrophy Type 2I (Lgmd2i/R9) Based on Glycosylated Alpha-Dystroglycan (Dg) Levels and Announces First Patient Dosed in Fortify Phase 3 Study

Bridgebio Announces Consistently Positive Results from Phase 3 Attribute-Cm Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma, Inc. Presents Updated Six Month Results from Its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia

Full year 2022 earnings released: US$3.26 loss per share (vs US$3.90 loss in FY 2021)

Bridgebio Pharma, Inc. Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

BridgeBio Pharm and ML Bio Solutions Present 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

BridgeBio Pharma, Inc Presents Updated Positive Data from Its BBP-812 Canavan Disease Gene Therapy Program At the 51st Annual Meeting of the Child Neurology Society

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 Inhibitor BBP-398 in Combination with Amgen's Lumakras(R) (Sotorasib)

BridgeBio Pharma, Inc. to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium

BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

BridgeBio Pharma, Inc Announces Dosing of First Patient in Phase 1 Trial of BBP-671

BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

BridgeBio Pharma, Inc. Announces Positive Interim Results from PROPEL 2

BridgeBio Pharma, Inc. and Sentynl Therapeutics, Inc. Receive Positive CHMP Opinion for NULIBRY® (Fosdenopterin) for Treatment of MoCD Type A

BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers

BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease

BridgeBio Pharma, Inc. Shares Positive Phase 2B Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)

BridgeBio Pharma, Inc. and Venthera, Inc. Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations

BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias

BridgeBio Pharma, Inc. and Phoenix Tissue Repair, Inc Announce Positive Results from Phase 2 Trial of PTR-01

BridgeBio Pharma, Inc., Annual General Meeting, Jun 22, 2022

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Sentynl Therapeutics Inc. entered into an asset purchase agreement to acquire Global Rights to NULIBRY from BridgeBio Pharma, Inc. (NasdaqGS:BBIO).

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

Independent Director recently bought €264k worth of stock

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age